The DESTINY-PanTumor-02 trial confirmed the pan-cancer efficacy of trastuzumab deruxtecan (T-Dxd) by treating 267 patients across different tumor cohorts (including endometrial, cervical, biliary tract, and pancreatic) with HER2 overexpression confirmed through IHC (IHC2+ or IHC3+) with the antibody-drug conjugate. Here, ERBB2 is linked to neoplasm.